Compare Gilead Sciences, Inc. (GILD) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Annaly Capital Management, Inc. — how do they compare? Gilead Sciences, Inc. trades at $132.93 (market cap $163.51B), while Annaly Capital Management, Inc. trades at $23.44 (market cap $16.97B). The key difference: Gilead Sciences, Inc. is far larger — about 9.6× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (12.95%). Which is the better fit depends on your goals.
| GILD | NLY | |
|---|---|---|
Market Cap | $163.51B | $16.97B |
Sector | Health | Financials |
52-Week High | $155.80 | $24.40 |
52-Week Low | $108.22 | $19.69 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 12.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
NLY trades at $23.01, up 2.13% today, with a bullish technical signal from moving averages and a consensus analyst price target of $24.40. The stock shows strong profitability with a 91.17% net income margin and 15.61% ROE, supported by recent earnings beats. A dividend yield of approximately 13% attracts income investors, though cash flow volatility and high leverage pose risks. Recent news highlights sensitivity to interest rate changes and earnings growth potential.
Outlook: NLY offers high dividend income and earnings momentum, but investors face interest rate sensitivity and balance sheet leverage. Upside depends on stable Fed policy and mortgage spread management, while downside risks include economic shifts affecting refinancing demand and funding costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
